Lupin Moves Into Russia With Biocom Buy
This article was originally published in PharmAsia News
Executive Summary
Lupin has snapped up the Russian generic firm, ZAO Biocom, sticking to its stated intent of M&A being one of the key drivers of its future as a global generic and specialty company.
You may also be interested in...
Lupin's Metformin US Outlook Stays Sunny; Russian Buy Under Review
Lupin reported a strong set of numbers for the first quarter ended June and expects US sales of its generic version of Glumetza (metformin HCL extended-release tablets) to stay a key contributor despite imminent competition from Sun Pharma, among others. The Indian firm, though, appears to be re-evaluating its Russian acquisition.
With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
BI India’s First Woman MD May Have To Hit The Ground Running
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.
Need a specific report? 1000+ reports available
Buy Reports